Freakonomics Radio Episode 671: Why Has There Been So Little Progress on Alzheimer’s Disease?

Original Air Date: April 17, 2026
Host: Stephen J. Dubner
Guests: Matthew Schrag (Vanderbilt University Medical Center), Charles Piller (Science Magazine), excerpts from several researchers and relevant institutional statements.

Episode Overview

This episode seeks to unravel why, despite tens of billions of dollars in research, so little progress has been made in treating Alzheimer’s Disease. Host Stephen Dubner examines whether a dominant scientific theory—the amyloid cascade hypothesis—has stalled real advancement, and investigates allegations of manipulation and fraud that may have derailed the search for effective therapies. The episode features investigative journalist Charles Piller and neurologist/whistleblower Matthew Schrag, who expose deep problems at the intersection of science, medicine, academia, and regulatory bodies.

Key Discussion Points and Insights

1. The State and Scope of Alzheimer’s Disease Research

• Alzheimer’s affects over 7 million Americans, mainly over 65, with no cure or highly effective treatment in sight ([01:02]).
• The disease was first documented in 1906 but, despite National Institutes of Health (NIH) spending ~$4 billion/year (second only to cancer), progress remains stymied ([01:02]–[02:32]).
• Alzheimer’s is increasingly seen as a disease of both environmental exposure and social inequality ([05:52]).
  • Pollution, obesity, and lower educational attainment are risk factors ([05:52]–[07:18]).

2. Dominance of the Amyloid Hypothesis—and Its Problems

• Since the 1990s, Alzheimer’s research has centered on the amyloid cascade hypothesis (accumulation of beta-amyloid plaques causes the disease) ([10:33]–[12:25]).
• The field’s heavy focus on amyloid has absorbed most funding, leaving alternative avenues under-explored ([12:37], [48:31]).
• Matthew Schrag (11:08): “Since about 1990...the main thought in this field is that the plaques, this little beta amyloid protein...is the primary driver of the disease. A huge amount of the effort related to drug development has been dedicated to preventing it from accumulating or breaking it up.”

3. Whistleblowing and Uncovering Research Misconduct

a. Cassava Sciences and Simufilam ([14:42]–[22:01])

• Schrag was hired to analyze alleged data manipulation for the drug Simufilam, developed by Cassava Sciences.
  • Found image manipulation in key scientific papers supporting the drug ([17:49]).
  • Schrag and whistleblowers took concerns to the FDA and NIH, but faced sluggish, opaque responses ([19:46]–[21:12]).
  • DOJ initially indicted scientist Haoyan Wang for data fabrication but later dropped charges; Cassava paid a $40 million SEC settlement and abandoned the drug ([32:10]).

b. The Lesné and Ashe 2006 Nature Paper ([24:34]–[31:28])

• A pivotal 2006 paper, cited thousands of times, used manipulated images to support the amyloid oligomer hypothesis.
  • Retraction finally occurred in 2025, after years of university stonewalling ([30:56]).
  • Co-author Karen Ashe claimed no prior knowledge of manipulation ([31:28]).

c. Systemic Research Irregularities: The Masliah Dossier ([33:49])

• Investigation found egregious image manipulation across 132 papers by Eliezer Masliah, who also ran the neuroscience division at the NIH’s National Institute on Aging ([33:49]–[36:25]).
• The NIH, when presented with evidence, waited until just as the exposé was published to announce Masliah was out of his director role ([36:35]–[37:33]).
  • Charles Piller: “You’re entrusting the organization that has the most to lose...with investigating possible misconduct. This is exactly the wrong approach.” ([29:29])

d. Reckoning with Personal Betrayal: Schrag and His Mentor ([39:30]–[46:31])

• Schrag discovers his undergraduate mentor, Othman Greeby, manipulated images in several co-authored papers, including Schrag’s earliest work ([39:30]–[43:09]).
  • Greeby admits to “polishing” images but denies outright fabrication ([41:54], [46:31]).
  • Schrag expresses deep personal pain but insists on upholding scientific integrity.
    • Schrag: “A lot of times people who have trouble in one domain can still have a lot of value to bring to the table... I told him that if he could find it in himself to speak out... that his role as a teacher could just be exponentially more important.” ([43:32])

4. Systemic Failures in Scientific Oversight and Regulatory Capture

• Academic and governmental self-investigation is fundamentally flawed ([29:29]) and often too slow to protect the integrity of science.
• The episode exposes “regulatory capture”—where FDA officials involved in drug approval move to lucrative industry jobs after approving questionable drugs ([48:31]–[49:08]).
  • Piller: “This drug [Aducanumab] was essentially the product of regulatory capture... Working hand in glove with the company that was promoting and trying to get the drug approved.” ([49:08])

5. The Narrow Focus’ Cost to Science and Patients

• Billions have been spent on anti-amyloid therapies, but treatments offer only minimal (often clinically insignificant) slowing of decline and carry real risks ([53:08]–[56:04]).
  • Piller: “They are dangerous. They can cause brain swelling and bleeding that has... resulted in death. Third, they're not effective in arresting the symptoms of the disease.” ([54:29])
• The “monoculture” of the amyloid hypothesis has stifled innovation by making funding for alternative hypotheses very difficult ([56:04], [59:14]).

6. A Way Forward—Expanding the Research Framework

• Schrag suggests refocusing Alzheimer’s as a waste clearance disorder, not just about amyloid or tau, integrating vascular health and other pathways ([56:11]–[57:59]).

  • Aggressive blood pressure control shows actual memory benefits—potential clues for broader strategies ([57:40]).
  • Need for research “renaissance” mirroring progress in stroke and epilepsy ([58:02]).
  • Diversity in research hypotheses should be encouraged.

• Memorable Quote (Matthew Schrag, 60:08):
  “One is that we need our memories to last a lifetime, to really get everything out of life that we're trying to get out of life.... A lot of the benefit of [medical] advances are being lost to this disease. If those extra years... are of poor quality, this is something that affects all fields and a huge number of people.... There must be something that we can do about it. This is one of the challenges for our generation, is to crack the code on this set of diseases, to make sure that the quality of life at the end of the life is what it should be.”

Notable Quotes & Memorable Moments

• Charles Piller (02:32): “No one’s getting better with these drugs. Every scientist who works with them, every clinician will say the same. If they don’t, they’re lying.”
• Matthew Schrag (13:57): “I think I probably would [blow the whistle again], simply because of how I’m wired... But sometimes you need to make a decision and just go with it.”
• Matthew Schrag (18:29): “There's a difference between seeing something suspicious and being able to prove it. ... Not random things, not accidents or slips... but a coherent pattern.”
• Charles Piller (48:31): “Nearly all of them have built their careers on explaining, exploring, and expanding the benefits and the importance of the amyloid hypothesis. Their money, their prestige ... all tied up with that.”
• Charles Piller (51:54): “Trust must be earned.... We can be highly critical of attacks on science... and at the same time, we can insist that the institutional authorities of science ... do better at their jobs.”
• Matthew Schrag (62:02): “There's definitely been some degree of backlash, and I think that's expected and almost unavoidable. Some opportunities lost, but I think that's okay. There's also other opportunities gained.”

Timestamps for Important Segments

• [01:02] – Introduction to Alzheimer’s, scale of the disease, and NIH funding.
• [05:52] – Environmental and socioeconomic contributors to risk.
• [10:33] – The amyloid/tau model and the dominance of the amyloid cascade hypothesis.
• [13:41] – Matthew Schrag’s dual role as researcher and whistleblower.
• [14:42] – Whistleblowing case: Cassava Sciences and Simufilam.
• [24:34] – 2006 Nature paper and image manipulation at University of Minnesota.
• [29:29] – Flaws in research oversight and university self-policing.
• [33:49] – Systemic problems: The Eliezer Masliah case at NIH.
• [39:30] – Matthew Schrag’s personal and professional reckoning with his mentor’s misconduct.
• [48:31] – “Cabal” of self-interested researchers, regulatory capture, and institutional conflict of interest.
• [53:08] – Effectiveness and cost of anti-amyloid drugs, and criticisms thereof.
• [56:11] – Rethinking Alzheimer’s as a “waste clearance” failure; blood vessel health as a target.

Thematic Takeaway

The episode powerfully exposes how entrenched scientific dogma, conflicts of interest, and failures in oversight have repeatedly delayed meaningful progress against Alzheimer’s. As the field has rewarded confirmation of the amyloid hypothesis, suppressed dissenting hypotheses, and tolerated research misconduct, patients and families have borne the cost. The way forward, as advocated by Schrag and Piller, requires a broader view of disease mechanisms, honest reckoning with past errors, research integrity, and institutional reforms to revive genuine innovation.

Further Reading

• Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s by Charles Piller
• Investigative articles in Science Magazine on Alzheimer’s research oversight

For feedback or discussion, email radio@freakonomics.com or find Freakonomics Radio on social platforms.